What is Impact BioMedical, Inc.?
discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
IBO · Verdict
Moderate reward · elevated risk
IBO's standout is volatility; balance sheet and cash flow weigh on the picture.
Based on 88% data coverage
IBO · Verdict
Top decile vs peers
Current ratio 0.25
-242% free-cash-flow margin
-88% net margin · -347% ROE
Below average
Model-based scoring. For information only — not financial advice.
discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 44.99M.
The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.